Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Reporting Period: Quarterly Report on Form 10-Q for the period ended December 31, 2001.
Status: Development-stage company focused on cell therapy technologies and the AastromReplicell™ System. The company has never been profitable and relies on equity financing and grants.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2001 | Six Months Ended Dec 31, 2000 |
|---|---|---|
| Total Revenues | $418,000 | $462,000 |
| Net Loss | $(3,913,000) | $(2,322,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.10) | $(0.07) |
| Cash and Cash Equivalents (End of Period) | $8,781,000 | $2,926,000 |
| Short-term Investments | $4,502,000 | $0 |
| Total Liquid Assets | $13,283,000 | $2,926,000 |
| Accumulated Deficit (Inception to Date) | $(89,771,000) | N/A |
| Current Liabilities | $986,000 | N/A |
Revenue Breakdown (Six Months 2001): Grants ($338,000) and Product Sales/Rentals ($80,000).
Expense Breakdown (Six Months 2001): R&D ($2,603,000), SG&A ($1,850,000), Cost of Sales ($106,000).
Material Changes vs. Prior Period
- Increased Losses: Net loss for the six months ended Dec 31, 2001, increased to $3.9 million from $2.3 million in the prior year period. This was driven by expanded R&D and marketing activities.
- Revenue Decline: Total revenues decreased slightly to $418,000 from $462,000 year-over-year, primarily due to lower grant funding.
- Expense Increases: R&D expenses rose to $2.6 million (from $1.985 million) and SG&A expenses rose to $1.85 million (from $1.173 million). Cost of product sales included a $106,000 charge for inventory reserves.
- Liquidity Improvement: Cash and short-term investments increased significantly to $13.3 million from $2.9 million, fueled by $6.8 million in equity financing during the period.
- Share Count: Weighted average shares outstanding increased to 41.1 million (from 33.7 million) due to equity issuances.
Outlook, Risks, and Management Commentary
- Liquidity Outlook: Management expects current cash reserves to fund operations through the end of calendar year 2002. The company anticipates needing additional funding to continue R&D and commercialization.
- Commercialization: The company has obtained CE Mark approval for its AastromReplicell™ System and specific kits (SC-I, CB-I, DC-I) for the European market. U.S. commercialization is pending FDA approval.
- Key Risks:
- Funding: Inability to raise capital could force substantial reductions in operations.
- Regulatory: Failure to obtain FDA approval or delays in clinical trials would severely limit marketability.
- Market Acceptance: Competition from standard stem cell procedures and potential lack of third-party reimbursement.
- Supply Chain: Reliance on third-party suppliers for critical components and growth factors.
- Delisting: Risk of Nasdaq delisting if stock price or tangible net worth requirements are not met.
- Unusual Items: The filing notes a $106,000 inventory reserve charge related to excess AastromReplicell™ inventory.
Investor Verification Checklist
- Verify the timeline and status of FDA clinical trials for the AastromReplicell™ System and DC-I product.
- Confirm the sufficiency of the $13.3 million cash balance to sustain operations through 2002 given current burn rates.
- Assess the progress of European sales and marketing activities following CE Mark approval.
- Review the terms of the new shelf registration filed in November 2001 for potential future dilution.
- Monitor stock price volatility and compliance with Nasdaq listing requirements (minimum bid price and net equity).